EveryONE Medicines
Kent Rogers currently serves as the Chief Executive Officer of EveryONE Medicines, a position held since July 2024. Additionally, Kent is a Board Member at SlateRx and a Venture Partner at ARCH Venture Partners, contributing to investments in disruptive science companies. Previously, Kent held key roles including Chief Commercial Officer at EQRx, Senior Vice President and Chief Industry Relations Officer at Optum, and Vice President of Global Market Access at Acorda Therapeutics. Kent's career spans over 30 years in the pharmaceutical and biotechnology sectors, demonstrating extensive expertise in strategic commercialization, market access, and industry relations. Educational qualifications include an MBA in International Business from Emory University's Goizueta Business School and a Bachelor of Science in Business Management and Organizational Change from Indiana University Bloomington.
This person is not in any teams
EveryONE Medicines
EveryONE Medicines is committed to developing individualized precision medicines targeting genetic variants causing fatal, neurodegenerative diseases unique to just a few or even ONE patient. Momentum is building as technological advances with genomic testing and the prevalence of testing is improving rapidly to identify the rarest of rare mutations. Through a collaborative effort across all stakeholders in the treatment and diagnosis of rare genetic disease, EveryONE Medicines will bring a scalable solution to meet the needs of the individual patient who currently has limited hope.